COR
Cencora Sees Strong Q2 Results, Raises Guidance Amid Pharmaceutical-Centric Strategy
Cencora recently reported its fiscal 2025 second quarter results, showcasing significant growth and continued expansion in key markets. The company delivered revenue growth of 10% and adjusted diluted earnings per share (EPS) growth of 16%, exceeding expectations. In a recent conference call to discuss the quarterly performance, Robert Mauch, President